BIOMAT Database Logo BIOMAT Database Logo

Growth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature. 1992

Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Institute of Pediatric and Adolescent Endocrinology, Beilinson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel.

Insulin-like growth factors (IGFs) mediate the effects of growth hormone (GH), and the insulin-like growth factor-binding proteins (IGFBPs) modulate the actions of IGFs in tissues. We studied the circulating levels of IGFBP-1 in 6 children and 9 adults with Laron type dwarfism (LTD), in 11 children and 21 adults with growth hormone deficiency (GHD), and in 8 children with constitutional short stature. Compared with the situation in healthy children, the basal serum IGFBP-1 concentration was 5.4-fold higher in LTD children, 4.1-fold higher in GHD children, and 3.8-fold higher in children with short stature (p < 0.02 vs controls in all groups). In adult patients with multiple pituitary hormone deficiency (MPHD), the IGFBP-1 concentration was 2-fold elevated, but it was normal in adult LTD patients. Intravenous (N = 10) or subcutaneous (N = 9) administration of IGF-I (75 micrograms.kg-1 and 150 micrograms.kg-1, respectively) in LTD children resulted in a rapid 50-60% fall in serum insulin (p < 0.02), a decline in blood glucose and a concomitant 40-60% rise of IGFBP-1 levels (p < 0.05). Treatment for seven days with IGF-I (150 micrograms.kg-1 x d-1) resulted in a decrease by 34% and 44% of serum IGFBP-1 level in two out of three children with LTD. After prolonged GH therapy, the IGFBP-1 level fell in GHD children by 29% (p < 0.05), in GHD adults by 52% (p < 0.02) and in children with constitutional short stature by 17% (p < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004392 Dwarfism A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height. Nanism
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism.
January 1992, The Journal of clinical endocrinology and metabolism,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Evaluation of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children.
January 2009, Journal of Ayub Medical College, Abbottabad : JAMC,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Etiological study of short stature in children and role of insulin like growth factor-1 and insulin like growth factor binding protein-3 as screening markers for growth hormone deficiency.
February 2023, JPMA. The Journal of the Pakistan Medical Association,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Absence of the plasma growth hormone-binding protein in Laron-type dwarfism.
October 1987, The Journal of clinical endocrinology and metabolism,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism).
July 1987, Proceedings of the National Academy of Sciences of the United States of America,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Laron-type dwarfism is associated with normal growth hormone and insulin-like growth factor I gene restriction patterns.
June 1989, Israel journal of medical sciences,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
The role of insulin like growth factor (IGF)-1 and IGF-binding protein-3 in diagnosis of Growth Hormone Deficiency in short stature children.
July 2009, Indian journal of pediatrics,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Laron-type dwarfism with apparently normal high affinity serum growth hormone-binding protein.
August 1991, Clinical endocrinology,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.
January 2016, Hormone research in paediatrics,
Z Laron, and A M Suikkari, and B Klinger, and A Silbergeld, and A Pertzelan, and M Seppälä, and V A Koivisto
Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity.
February 1993, Acta endocrinologica,
Copied contents to your clipboard!